Koncept analytics global biosimilars market

930 views

Published on

Published in: Business, Health & Medicine
0 Comments
1 Like
Statistics
Notes
  • Be the first to comment

No Downloads
Views
Total views
930
On SlideShare
0
From Embeds
0
Number of Embeds
2
Actions
Shares
0
Downloads
0
Comments
0
Likes
1
Embeds 0
No embeds

No notes for slide

Koncept analytics global biosimilars market

  1. 1. View Report DetailsGlobal Biosimilars Market -------------------------------- 2012
  2. 2. View Report DetailsExecutive SummaryThe biosimilar market is presently a small segment of the pharmaceutical industry. However, in the years to come, the markethas huge growth opportunity despite of the high entry barriers. The governments in the developed countries are taking activesteps towards controlling their national healthcare expenditure. Furthermore, the patents for several original bio drugs areexpected to expire in the coming decade. These factors along with the new biosimilar guidelines by the US Food & DrugAdministration are paving the path for the growth of the biosimilar market.Biosimilars are generic version of bio drugs or off patent bio drugs, which are usually more cost effective compared to theoriginal version of the drug. So far, Europe has been the most developed market for biosimilars. The biosimilar market in theEurope is strictly governed by European Medicines Agency (EMA).The global biosimilar market is expected to become highly competitive in the coming years as original chemical drug makers,generic chemical drug makers, and original bio drug makers are entering into biosimilars business seeing the growth potential ofthe market. Within the biosimilar market, the pipeline for anti- TNF biosimilars is quite higher compared to other biosimilars.It is expected that the market for Epoetin alpha and Insulin-glargine biosimilars will grow significantly during 2010-2015 in thedeveloped countries, mainly driven by cost containment efforts from the US and European governments. Within the global firstgeneration biosimilar market, the market for G-CSF biosimilar recorded huge growth in 2010 compared to the previous year.The growth of the biosimilar market is mainly driven by rising aging population, growing healthcare expenditure, growingworldwide economy, and patent expiries of market leading bio drugs. New technologies like recombinant DNA technology,protein sequencing, protein electrophoresis, and western blotting are also expected to have a positive impact on the market.However, requirement of extensive clinical trials for obtaining approval, lower profit margins, and lower return on investmentscontinues to challenge the attractiveness of the biosimilars market.The report analyzes the global biosimilars market. The various drivers and challenges faced by the market are discussed indetail. The competitive landscape of the market is also highlighted and the key players are profiled with their key businessstrategies.
  3. 3. Strong growth of global bio drugs market on the back of growing size of biosimilarpipeline and patent expiry of bio drugs… Global Bio Drugs Market  The worldwide market for bio drugs was valued at US$......................................................in 2006, which is expected to reach …………………………….. in 2011, registering a CAGR of ………………..during the mentioned period. In 2011,…………………... ………………………………………………………………….  The biosimilar market is …………. yet tough to …….. as US$ Billion manufacturing and selling biosimilars is ……. ………………………….. …………………………………………………………………………  The value of Anti-TNF biosimilar pipeline was US$........ billion in 2010, whereas the pipeline value of ………………….. was US$......billion in the mentioned year. ………………………………………………………... ………………………………………………………………………… 2006 2007 2008 2009 2010 2011 Size of Global Biosimilar Pipeline Global Market Status of Off-Patent Bio Drugs US$ Billion US$ Billion Interferon A Interferon B Modern Insulins Heparin Blood factors Filgrastim Epoetin A/B Anti‐TNF Other MABs 2008 2009 2010 2011E
  4. 4. Significant growth opportunity of global biosimilars market and global biologicsmarket supported by the growth of first generation biosimilars… Worldwide Revenue of Biosimilars and Biologics Market  The global biosimilar market was valued at US$............................. in 2009, which is estimated to reach US$........... in 2015, registering a CAGR of …………………….. The global biologics market is expected to reach US$.................. billion in 2015 US$ Billion ………………………………………………………………… …………………………………………………………….…… …..  The global market for EPO alpha was valued at US$.................................... million in 2009, which increased by …….% to reach US$.......................in 2010. ………………………………………………………………… ……………………………………………………US$.............. 2009 2010 2011F 2012F 2013F 2014F 2015F ............million from US$....................... million in 2009. The ………..and ……………. were the leading ……….markets Global Biosimilar Global Biologics ………………………………………………………………… …………………………………………………………… Global First Generation Biosimilar Market Status US$ Million EPO alpha Somatropin G-CSF 2009 2010
  5. 5. The US represents a significant market for biologics products and is expected tocontinue strong performance in coming years… Sales of Biologics Products in the US as a Percentage of Global Market Erythropoietin G-CSF Inte rferon alpha Inte rferon beta Hum an Growth horm one • The US is …………………………………….. for biologics products. In 2010, the US accounted for ………………………… of the global market for Erythropoietin and ……………………………….of G-CSF market. During the same year, the US also emerged as the largest market for …………………… and …………………………….. The US accounted for …………………% of the global ……………………… market and …………………………….% of the human growth hormone in 2010. ………………………………… ……………………………………………………………………………………………………………………………………………………… ………………………………………………………………………………….
  6. 6. View Report DetailsTable of Contents List of Charts1. Biosimilars: An Introduction SWOT Analysis of Biosimilars Market Biosimilar Development Process and Investment Costs1.1 Overview Competition in the Biosimilar Market1.2 Differences between Biosimilars and Biobetters Global Bio Drugs Market, 2006-20111.3 Manufacturing of Bio Drugs Global Market Status of Off-Patent Bio Drugs, 2008-20111.4 FDA’s Guidance on Biosimilars in the US Size of Biosimilar Pipeline, 20101.5 Present Market Conditions Revenue of Biosimilar & Biologics Products in Developed Countries, 2009- 2015F2. Biosimilars Market Worldwide Revenue of Biosimilars and Biologics Market, 2009-2015F Global First Generation Biosimilar Market Status, 2009-20102.1 Worldwide Market Expected Breakup of Global Drug Market, 2015EMarket Value Sales of Biologics Products in the US as a Percentage of Global Market,Revenue Trend in Developed Countries 2010Product Pipeline Global Healthcare Spending, 2005-2015E Growth of Global Aging Population, 2005-2012EMarket Statistics World GDP per Capita, 2005-2010 Major Players in the Global Biosimilar Market, 20112.2 Biotech Product Market in the US Market Share of Major Players in the European biosimilars market, 20102.3 Biosimilar Market in Europe Net Sales of Hospira by Reportable Segments, 20112.4 Bio Drug Market in Korea Net Sales & Net Income of Hospira, 2007-2011 Teva Share of Revenue by Reportable Segment, 20113. Key Trends Net Revenues and Net Income of Teva, 2007-2011 Sales of Merck & Co. by Segments3.1 Global Drug Makers Rushing to Develop Biosimilars Net Sales and Net Income of Merck & Co., 2007-20113.2 Urgent Requirement of Biosimilars in the US Novartis Share of Sales by reportable Segments, 20113.3 Policies of European Government to Control Healthcare Net Sales and Net Income of Novartis, 2007-2011Expenditure4. Growth Drivers4.1 Rising Healthcare Expenditure4.2 Rising Ageing Population4.3 Growing Worldwide Economy4.4 Upcoming Patent Expiries of Original Bio Drugs
  7. 7. View Report Details5. Significant developments List of Tables5.1 Recombinant DNA Technology Positives and Negatives of Biosimilar Industry5.2 Protein Sequencing Method Global Market for Top Selling Bio Drugs, 2010-2016F5.3 Protein Electrophoresis Major Biosimilar Product Revenues Trends in Developed5.4 Western Blotting Countries, 2009A-2015F5.5 Monoclonal Antibodies (MAB) Technology Clinical Development Cost of Monoclonal Antibodies, 2011E Biosimilars Approvals in Europe, 2006-20096. Challenges Sales of Bio Drugs in Korea, 2007-2011 Expiry of Bio Drugs Patents in the Global Market, 2012-20196.1 Requirement of Extensive Clinical Trials for ObtainingApproval6.2 Strong Marketing Capabilities Required6.3 Lower Margins in Biosimilars6.4 Concern over Return on Investments of Biosimilars7. Biosimilars Market - Competitive LandscapeCompetitive OverviewMarket Share8. Company Profile8.1 Hospira Inc.Business DescriptionKey FinancialsBusiness StrategiesProduct Development StrategyAchieving Product Differentiation8.2 Teva Pharmaceutical Industries LimitedBusiness DescriptionKey FinancialsBusiness Strategies
  8. 8. View Report DetailsIncreasing Generic Market ShareExpanding OTC Opportunities8.3 Merck & Co., Inc.Business DescriptionKey FinancialsBusiness StrategiesR&D StrategyMerger Restructuring Program8.4 Novartis AGBusiness DescriptionKey FinancialsBusiness StrategiesLeadership in InnovationDriving Productivity of the Organization9. Market Outlook
  9. 9. View Report Details Contact Us:These are abridged and sanitized sample pages from the comprehensive report on the “Global Biosimilars Market Report”. Toknow more about this report or for any customized research requirement, please contact the following: Koncept Analytics CS-36, Second Floor, Ansal Plaza Vaishali, Ghaziabad, U.P. – 201010 Vikas Gupta T. +91-120-4130959 BD Manager C: +91-9811715635 vikas@konceptanalytics.com www.konceptanalytics.com

×